CGRP and migraine pathophysiology: New insights for targeted prevention
Migraine is the most prevalent neurological disorder worldwide1 and has been, until now, treated with preventive therapies originally indicated for other diseases.1 Recently, blocking calcitonin gene-related peptide (CGRP) has emerged as a target for migraine prevention.1 As part of the satellite symposium on “Anti-calcitonin gene-related peptide monoclonal anti
Login to register to read this article
If you do not have a Log in, please register to be part of a big community, experience premium content and stay informed about exclusive professional events.
Log InNot registered yet? Register now